Claritas Pharmaceuticals Inc CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

GREY:CLAZF - Post by User

Claritas Pharmaceuticals Inc > Maybe try reading the news release? Right your one of those

<< Previous

Bullboard Posts

Next >>

Comment by Scottyon Jan 16, 2021 8:36am

206 Views

Post# 32312865

RE:Maybe try reading the news release? Right your one of those

Right, so you didn't read the release did you? Can you read? Maybe you should ask Bob to send you an audio recording of it. Beyond that, how do you think this company will raise money moving forward? Waves upon waves of dilution, to keep the lights on and fund another companies patent. Even after a 20:1 this company will be back to pennies in a few years, if they can manage to sucker some more people into this scam.

<< Previous

Bullboard Posts

Next >>

Corus reports Q1 profit drop in the face of falling revenue